| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.02 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.02 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | BHG712 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.03 |